letrozole / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 114 Diseases   361 Trials   361 Trials   7200 News 


«12...1314151617181920212223...100101»
  • ||||||||||  Kisqali (ribociclib) / Novartis
    Enrollment closed, Enrollment change, Trial primary completion date, Combination therapy, Metastases:  FACILE: FeAsibility of First-line riboCIclib in oLdEr Patients With Advanced Breast Cancer (clinicaltrials.gov) -  Sep 22, 2023   
    P2,  N=116, Active, not recruiting, 
    Trial completion date: Oct 2023 --> Oct 2025 | Trial primary completion date: Oct 2023 --> Oct 2025 Recruiting --> Active, not recruiting | N=194 --> 116 | Trial primary completion date: Dec 2022 --> Dec 2024
  • ||||||||||  Verzenio (abemaciclib) / Eli Lilly
    Trial completion date, Metastases:  MONARCH plus: A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer (clinicaltrials.gov) -  Sep 21, 2023   
    P3,  N=463, Active, not recruiting, 
    Recruiting --> Active, not recruiting | N=194 --> 116 | Trial primary completion date: Dec 2022 --> Dec 2024 Trial completion date: Sep 2023 --> Dec 2024
  • ||||||||||  metformin / Generic mfg., letrozole / Generic mfg.
    Preclinical, Journal:  Pharmacological Potential of Hippophae rhamnoides L. Nano-Emulsion for Management of Polycystic Ovarian Syndrome in Animals' Model: In Vitro and In Vivo Studies. (Pubmed Central) -  Sep 18, 2023   
    Letrozole (1 mg/kg) was used for 5 weeks to induce the disease...After PCOS induction, animals were treated with metformin, HR, and HRNE with two different doses (0.5/kg and 1 g/kg, p.o.) for 5 weeks...Results were statistically analyzed by one-way analysis of variance and were considered significant only if p < 0.05. In conclusion, it can be postulated that H. rhamnoides L. proved effective in the management of PCOS and its nano-emulsion effects were statistically more significant, which might be due to better bioavailability.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Retrospective data, Journal:  Influence of non-osteoporotic treatments in patients on active anti-osteoporotic therapy: evidence from the OSTEOMED registry. (Pubmed Central) -  Sep 18, 2023   
    The potential beneficial or detrimental effects of the different drugs evaluated on fracture risk are masked by treatment with anabolic or antiresorptive drugs that have a more potent action on bone metabolism, with two exceptions: letrozole and oral corticosteroids. These findings may have important clinical implications, as patients receiving these treatments are not fully protected by bisphosphonates, which may imply the need for more potent anti-osteoporotic drugs such as denosumab or teriparatide.
  • ||||||||||  letrozole / Generic mfg.
    Journal:  Outcomes of random-start letrozole protocol with PGT-A in women with breast cancer undergoing fertility preservation. (Pubmed Central) -  Sep 18, 2023   
    These findings may have important clinical implications, as patients receiving these treatments are not fully protected by bisphosphonates, which may imply the need for more potent anti-osteoporotic drugs such as denosumab or teriparatide. Our data suggests that RSCOS fertility preservation cycle outcomes are similar to those with SSCOS and result in age-appropriate euploidy rates.
  • ||||||||||  letrozole / Generic mfg., anastrozole / Generic mfg.
    Trial completion, Trial completion date, Trial primary completion date:  Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer (clinicaltrials.gov) -  Sep 15, 2023   
    P2,  N=161, Completed, 
    Our data suggests that RSCOS fertility preservation cycle outcomes are similar to those with SSCOS and result in age-appropriate euploidy rates. Active, not recruiting --> Completed | Trial completion date: Jun 2024 --> Dec 2022 | Trial primary completion date: Jan 2024 --> Dec 2022
  • ||||||||||  letrozole / Generic mfg.
    Preclinical, Journal:  Effect of quercetin on steroidogenesis and folliculogenesis in ovary of mice with experimentally-induced polycystic ovarian syndrome. (Pubmed Central) -  Sep 8, 2023   
    Eighteen mature parkes strain mice (4-5 weeks old) weighing18-21 g were randomly divided into three groups of six each as follows: Group I serves as the control and was given water and a regular chow diet ad lib for 66 days; group II was given oral gavage administration of letrozole (LETZ) (6 mg/kgbw) for 21 days to induce PCOS and was left untreated for 45 days; For three weeks, Group III received oral gavage dose of LETZ (6 mg/kg), after which it received Quercetin (QUER) (125 mg/kg bw orally daily) for 45 days...the Side effects of Quercetin have to be targeted in future researches. Quercetin may act as a promising candidate for medical management of human PCOS.
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Trial completion date, Trial primary completion date:  Comparison Between Letrozole and Mifepristone in Medical Termination of First Trimester Miscarriages (clinicaltrials.gov) -  Sep 6, 2023   
    P3,  N=120, Recruiting, 
    Quercetin may act as a promising candidate for medical management of human PCOS. Trial completion date: May 2023 --> May 2024 | Trial primary completion date: Apr 2023 --> Apr 2024
  • ||||||||||  progesterone / Generic mfg., letrozole / Generic mfg.
    Biomarker, Preclinical, Journal:  LC-MS/MS based quantification of steroidal biomarkers in polycystic ovary syndrome induced rats. (Pubmed Central) -  Aug 28, 2023   
    hydroxy progesterone), and T4 (Testosterone) were significantly altered...The pharmacokinetic data showed that, as compared to normal rats, PCOS-induced animals had significantly higher C values for 17OHP4 and T4 (?2 fold), while lower C values for P4 (?2 fold). The present work is novel and provides scientific information to explore systematic processes involved in steroidogenesis and boost clinical applicability for PCOS therapy.
  • ||||||||||  Verzenio (abemaciclib) / Eli Lilly
    Journal:  ESR1 Mutation-Positive Recurrent Breast Cancer Successfully Treated with Letrozole plus Abemaciclib (Pubmed Central) -  Aug 27, 2023   
    One of the resistance mechanisms is mutations in the ESR1 gene, which have also been found to occur after long-term aromatase inhibitor(AI)treatment. Here, we describe our experience of a case in which long-term PR was achieved with AI(letrozole)plus abemaciclib despite ESR1 mutation positivity in cancer genetic screening and review the literature.
  • ||||||||||  progesterone / Generic mfg., letrozole / Generic mfg.
    Preclinical, Journal:  Insights into Vitamin E with Combined Oral Contraceptive on INSR Gene in PCOS by Integrating In Silico and In Vivo Approaches. (Pubmed Central) -  Aug 23, 2023   
    Interestingly, vitamin E acts like the hormone progesterone and improves insulin sensitivity in PCOS...Additionally, in vivo studies with a letrozole-induced PCOS model were performed in 30 female SD rats (n = 6 in each group) for 8 weeks with different doses of vitamin E. Furthermore, histopathological features and the insulin receptor (INSR) gene were scrutinized...Ovarian histopathological changes were observed in different follicle counts in addition to the INSR gene, which showed changes in densitometry values. Supplementation of vitamin E combined with COC could be effective against PCOS, and clinical studies must be carried out further.
  • ||||||||||  letrozole / Generic mfg.
    Journal:  Single-cell sequencing provides insights into the landscape of ovary in PCOS and alterations induced by CUMS. (Pubmed Central) -  Aug 16, 2023   
    The PCOS rat model was established by letrozole while PCOS rat model with depression was established by letrozole combined with chronic unpredicted mild stress (CUMS)...Finally, analysis of T cells and mononuclear phagoytes (MPs) revealed the existence of immune dysfunction, among which interferon signaling played a critical role. These findings provided more acknowledge for better understanding PCOS from the view of inflammation and identified new biomarkers and targets for the treatment of PCOS with psychological diseases.
  • ||||||||||  maveropepimut-S (MVP-S) / BioVaxys
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date:  Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer (clinicaltrials.gov) -  Aug 14, 2023   
    P1,  N=6, Active, not recruiting, 
    Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=18 --> 6 | Trial completion date: Jun 2026 --> Sep 2026 | Trial primary completion date: Jun 2023 --> Sep 2023